Formation of cyclophosphamide specific DNA adducts in hematological diseases

Pediatric Blood and Cancer

Volumn 58, Issue 5, 2012, Pages 708-714

  Johnson, L'Aurelle A ^a   Malayappan, Bhaskar ^a   Tretyakova, Natalia ^a   Campbell, Colin ^a   Macmillan, Margaret L ^a   Wagner, John E ^a   Jacobson, Pamala A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Cyclophosphamide; DNA adducts; Fanconi anemia; Transplantation

Indexed keywords

CYCLOPHOSPHAMIDE;

AREA UNDER THE CURVE; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DNA CROSS LINKING; DRUG BLOOD LEVEL; DRUG RESPONSE; FANCONI ANEMIA; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IN VIVO STUDY; LOW DRUG DOSE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DNA ADDUCTS; FANCONI ANEMIA; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED;

EID: 84857865946     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23254     Document Type: Article

References (26)

1. Auerbach AD. Fanconi anemia and its diagnosis. Mutat Res 2009; 668: 4-10.
2. Parmar K, D'Andrea A, Niedernhofer LJ. Mouse models of Fanconi anemia. Mutat Res 2009; 668: 133-140.
3. van der Heijden MS, Brody JR, Dezentje DA, et al. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 2005; 11: 7508-7515.
4. van der Heijden MS, Brody JR, Gallmeier E, et al. Functional defects in the Fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 2004; 165: 651-657.
5. Dalle JH. HSCT for Fanconi anemia in children: Factors that influence early and late results. Bone Marrow Transplant 2008; 42: S51-S53.
6. Gluckman E. Allogeneic bone marrow transplantation in Fanconi anemia. Bone Marrow Transplant 1996; 18: S33-S35.
7. Maccubbin AE, Caballes L, Riordan JM, et al. A cyclophosphamide/DNA phosphoester adduct formed in vitro and in vivo. Cancer Res 1991; 51: 886-892.
8. Hemminki K. DNA-binding products of nornitrogen mustard, a metabolite of cyclophosphamide. Chem Biol Interact 1987; 61: 75-88.
9. Hemminki K. Binding of metabolites of cyclophosphamide to DNA in a rat liver microsomal system and in vivo in mice. Cancer Res 1985; 45: 4237-4243.
10. O'Connor PM, Kohn KW. Comparative pharmacokinetics of DNA lesion formation and removal following treatment of L1210 cells with nitrogen mustards. Cancer Commun 1990; 2: 387-394.
11. Akkari YM, Bateman RL, Reifsteck CA, et al. DNA replication is required to elicit cellular responses to psoralen-induced DNA interstrand cross-links. Mol Cell Biol 2000; 20: 8283-8289.
12. Sobeck A, Stone S, Costanzo V, et al. Fanconi anemia proteins are required to prevent accumulation of replication-associated DNA double-strand breaks. Mol Cell Biol 2006; 26: 425-437.
13. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 2003; 3: 23-34.
14. Grompe M, D'Andrea A. Fanconi anemia and DNA repair. Hum Mol Genet 2001; 10: 2253-2259.
15. Pagano G, Manini P, Bagchi D. Oxidative stress-related mechanisms are associated with xenobiotics exerting excess toxicity to Fanconi anemia cells. Environ Health Perspect 2003; 111: 1699-1703.
16. Pagano G, Youssoufian H. Fanconi anaemia proteins: Major roles in cell protection against oxidative damage. BioEssays 2003; 25: 589-595.
17. Pagano G, Korkina LG, Degan P, et al. In vitro hypersensitivity to oxygen of Fanconi anemia (FA) cells is linked to ex vivo evidence for oxidative stress in FA homozygotes and heterozygotes. Blood 1997; 89: 1111-1112.
18. Yule SM, Price L, Cole M, et al. Cyclophosphamide metabolism in children with Fanconi's anaemia. Bone Marrow Transplant 1999; 24: 123-128.
19. Malayappan B, Johnson L, Nie B, et al. Quantitative high-performance liquid chromatography-electrospray ionization tandem mass spectrometry analysis of bis-N7-guanine DNA-DNA cross-links in white blood cells of cancer patients receiving cyclophosphamide therapy. Anal Chem 2010; 82: 3650-3658.
20. Pieck AC, Drescher A, Wiesmann KG, et al. Oxaliplatin-DNA adduct formation in white blood cells of cancer patients. Br J Cancer 2008; 98: 1959-1965.
21. Veal GJ, Dias C, Price L, et al. Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy. Clin Cancer Res 2001; 7: 2205-2212.
22. Souliotis VL, Dimopoulos MA, Sfikakis PP. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards. Clin Cancer Res 2003; 9: 4465-4474.
23. Franssen C, Boekema P, De Witte T, et al. DNA strand breaks in human leukocytes induced by chemotherapy and total body irradiation. Leuk Res 1990; 14: 91.
24. Mohseni Meybodi, A, Mozdarani H. DNA damage in leukocytes from Fanconi anemia (FA) patients and heterozygotes induced by mitomycin C and ionizing radiation as assessed by the comet and comet-FISH assay. Iran Biomed J 2009; 13: 1.
25. Xie H, Griskevicius L, Stahle L, et al. Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. Eur J Pharm Sci 2006; 27: 54-61.
26. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007; 13: 853-862.